{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:16:02Z","timestamp":1791220562482,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,3,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine whether aprinocarsen, an antisense oligonucleotide directed against protein kinase C-alpha, when added to the chemotherapy regimen of gemcitabine and cisplatin improved survival in patients with advanced non\u2013small-cell lung cancer (NSCLC). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with previously untreated stage IIIB\/IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1, were randomly assigned to either a control arm of gemcitabine 1,250 mg\/m<jats:sup>2<\/jats:sup> on days 1 and 8 and cisplatin 80 mg\/m<jats:sup>2<\/jats:sup> on day 1, or experimental arms consisting of the identical chemotherapy plus aprinocarsen 2 mg\/kg\/d as continuous infusion for 14 days, starting on either day 1 or 3 days before chemotherapy. Cycles were repeated every 21 days. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 670 patients were randomly assigned between the control (n = 328) and experimental arms (n = 342). Due to the results from another phase III study of aprinocarsen in NSCLC, further enrollment was stopped, and the study was terminated early. The median number of cycles was four on the control arm and three on the combined experimental arms. Median overall survival was not different between the two groups (control, 10.4 months [95% CI, 8.6 to 12.2]; experimental, 10.0 months [95% CI, 8.4 to 10.8]; P = .613; hazard ratio = 1.05 [95% CI, 0.88 to 1.25]). Response rates (control arm, 35.0%; experimental arms, 28.9%; P = .124) and other time-to-event measures were not significantly different. Grade 3 and 4 toxicities were significantly increased for thrombocytopenia (P &lt; .0001), epistaxis, and thrombosis\/embolism in the experimental arms. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Adding aprinocarsen to gemcitabine and cisplatin regimen did not enhance survival and other efficacy measures in patients with advanced NSCLC. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.3299","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T23:58:03Z","timestamp":1142899083000},"page":"1428-1434","source":"Crossref","is-referenced-by-count":129,"title":["Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1200","volume":"24","author":[{"given":"Luis","family":"Paz-Ares","sequence":"first","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Koralewski","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Manegold","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Reyes","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"John","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Peterson","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman K.","family":"Obasaju","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lahn","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[{"name":"From the Servicio de Oncolog\u00eda M\u00e9dica, Doce de Octubre University Hospital, Madrid, Spain; Centre Ren\u00e9 Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Heidelberg University Medical Center, Mannheim, Germany; VU University Medical Center, Amsterdam, the Netherlands; Instituto de Oncolog\u00eda, Cl\u00ednica Las Condes, Santiago, Chile; Taichung Veterans General Hospital, Taichung, Taiwan, People\u2019s Republic of China; Commonwealth Cancer Center, Richmond, KY; Eli Lilly and Co,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"R2","unstructured":"Sandler A: State-of-the-art treatment for advanced non-small cell lung cancer. Oncology (Williston Park) 17: 15,2003 -22,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1038\/334661a0"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(93)90070-T"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Dean NM, McKay R, Condon TP, et al: Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269: 16416,1994 -16424,","DOI":"10.1016\/S0021-9258(17)34023-1"},{"key":"R6","unstructured":"Yuen AR, Halsey J, Fisher GA, et al: Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521\/CGP 64128A) in patients with cancer. Clin Cancer Res 5: 3357,1999 -3363,"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11909"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh359"},{"key":"R9","unstructured":"Yuen AR, Halsey J, Fisher GA, et al: Phase I\/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 20: 309a,2001 ,   (abstr 1234)"},{"key":"R10","unstructured":"Ritch PS, Belt R, George S, et al: Phase I\/II trial of ISIS 3521\/LY9000003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 309a,2002 ,   (abstr 1233)"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R12","unstructured":"Lynch TJ, Raju R, Lind M, et al: Randomized phase III trial of chemotherapy and antisense, oligonucleotide LY9000003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 22: 623,2003 ,   (abstr 2504)"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.017"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Sandler A, Gray R, Brahmer J, et al: Randomized phase II\/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E45 99. J Clin Oncol 24: 2a,2005 ,   (abstr 4)","DOI":"10.1200\/jco.2005.23.16_suppl.lba4"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-6736-x"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.001"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.215"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23: 617,2004 ,   (abstr 7010)","DOI":"10.1200\/jco.2004.22.90140.7010"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-9012"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2823"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh031"},{"key":"R24","unstructured":"Pierce LJ, Hutchins L, Green SJ, et al: Sequencing of tamoxifen (TAM) and radiotherapy (RT) with breast conservation (BCT) in early stage breast cancer. Proc Am Soc Clin Oncol 22: 10,2003 ,   (abstr 39)"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100293"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Morgan RJ, Doroshow JH, Frankel P, et al: A phase II trial of bryostatin in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California Cancer Consortium (CCC) trial. J Clin Oncol 24: 489s,2005 ,   (abstr 5140)","DOI":"10.1200\/jco.2005.23.16_suppl.5140"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2602"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0779"},{"key":"R29","unstructured":"Clark A, West K, Blumberg P, et al: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC\u03b4 promotes cellular survival and chemotherapeutic resistance. Cancer Res 63: 780,2003 -786,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.3299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:00:48Z","timestamp":1653512448000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.3299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,20]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,3,20]]}},"alternative-id":["10.1200\/JCO.2005.04.3299"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.3299","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,20]]}}}